Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

gracehh Jul. 31 at 1:00 AM

$EDHL $PLSE jett28

0 · Reply

Tjcmd Jul. 30 at 7:49 PM

$PLSE Abbots VOLT PFA system (approved 12/25) eliminates need for GA…one of the stated advantages of nsPFA…any EP docs care to weigh in?

1 · Reply

Tjcmd Jul. 30 at 7:40 PM

$PLSE what is the primary endpint in the study and will the results be good enough for cardiologists to switch from micro second PFA?

0 · Reply

PatrickandFrankie Jul. 29 at 5:24 PM

$PLSE is anybody buying this “sell the news” b.s. ??? Seems obvious to me that they are trying to steal our shares no one knew that they were WAY ahead of schedule on enrollment until today. That means way lower spend on clinical trials as time is money .. and that means if all goes well.. way sooner payoff in getting approval earlier than plan and rolling out to hospitals earlier than plan … makes no sense for stock to be down on this surprisingly excellent news imho

1 · Reply

prismmarketview Jul. 29 at 2:22 PM

$PLSE Pulse Biosciences's NANOPULSE‑AF pivotal study for nsPFA AFib ablation is now past halfway on enrollment, an important step toward future results and potential approval. #PLSE #AFib #ClinicalTrials https://prismmarketview.com/pulse-biosciences-hits-its-stride-nanopulse-af-afib-pivotal-trial-passes-enrollment-midpoint/

0 · Reply